Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EMR Emerson Electric	$144.16 -0.2%	$127.64	$90.06 ▼ $145.23	$81.09B	1.29	3.00 million shs	1.92 million shs
GS The Goldman Sachs Group	$708.31 +0.3%	$644.19	$437.37 ▼ $726.00	$217.34B	1.35	2.37 million shs	1.92 million shs
NFLX Netflix	$1,209.24 -5.1%	$1,231.20	$587.04 ▼ $1,341.15	$514.62B	1.59	3.80 million shs	10.68 million shs
PFE Pfizer	$24.46 -0.5%	$24.02	$20.92 ▼ $31.54	$139.06B	0.58	41.93 million shs	36.27 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EMR Emerson Electric	+2.97%	+2.69%	+13.23%	+45.08%	+22.14%
GS The Goldman Sachs Group	-0.17%	-0.38%	+13.19%	+38.60%	+40.79%
NFLX Netflix	+1.91%	+1.89%	+4.38%	+30.95%	+96.80%
PFE Pfizer	+0.02%	-4.55%	+2.46%	+11.14%	-18.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EMR Emerson Electric	4.6937 of 5 stars	2.3	5.0	4.2	2.1	3.4	2.5	1.3
GS The Goldman Sachs Group	4.8399 of 5 stars	2.1	4.0	4.2	3.0	3.2	1.7	3.1
NFLX Netflix	4.2742 of 5 stars	2.4	4.0	0.0	2.8	3.3	2.5	1.9
PFE Pfizer	4.9618 of 5 stars	3.2	3.0	4.2	4.5	2.6	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EMR Emerson Electric	2.68	Moderate Buy	$142.28	-1.31% Downside
GS The Goldman Sachs Group	2.24	Hold	$649.29	-8.33% Downside
NFLX Netflix	2.70	Moderate Buy	$1,275.30	5.46% Upside
PFE Pfizer	2.45	Hold	$28.55	16.72% Upside

Current Analyst Ratings Breakdown

Latest PFE, GS, EMR, and NFLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	NFLX Netflix	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$1,500.00
7/18/2025	NFLX Netflix	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$1,500.00 ➝ $1,560.00
7/18/2025	NFLX Netflix	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,450.00 ➝ $1,495.00
7/18/2025	NFLX Netflix	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$1,230.00 ➝ $1,300.00
7/18/2025	NFLX Netflix	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,440.00 ➝ $1,450.00
7/18/2025	NFLX Netflix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1,500.00
7/18/2025	NFLX Netflix	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$1,450.00 ➝ $1,500.00
7/18/2025	NFLX Netflix	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$1,400.00 ➝ $1,500.00
7/18/2025	NFLX Netflix	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,514.00 ➝ $1,515.00
7/17/2025	GS The Goldman Sachs Group	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$771.00 ➝ $790.00
7/17/2025	GS The Goldman Sachs Group	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$680.00 ➝ $715.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EMR Emerson Electric	$17.49B	4.64	$9.10 per share	15.85	$48.03 per share	3.00
GS The Goldman Sachs Group	$126.85B	1.71	$53.66 per share	13.20	$404.12 per share	1.75
NFLX Netflix	$39.00B	13.19	$55.04 per share	21.97	$57.85 per share	20.90
PFE Pfizer	$63.63B	2.19	$4.34 per share	5.64	$15.62 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EMR Emerson Electric	$1.97B	$4.18	34.49	22.35	2.72	13.60%	13.22%	7.57%	8/6/2025 (Estimated)
GS The Goldman Sachs Group	$14.28B	$43.09	15.61	13.60	0.97	12.37%	13.84%	0.89%	N/A
NFLX Netflix	$8.71B	$21.16	57.15	40.81	2.26	23.07%	39.61%	17.90%	N/A
PFE Pfizer	$8.03B	$1.38	17.72	8.07	0.90	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, GS, EMR, and NFLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q3 2025	EMR Emerson Electric	$1.51	N/A	N/A	N/A	$4.60 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
7/17/2025	Q2 2025	NFLX Netflix	$7.07	$7.19	+$0.12	$7.19	$11.04 billion	$11.08 billion
7/16/2025	Q2 2025	GS The Goldman Sachs Group	$9.82	$10.91	+$1.09	$10.91	$13.53 billion	$14.58 billion
5/7/2025	Q2 2025	EMR Emerson Electric	$1.41	$1.48	+$0.07	$0.86	$4.42 billion	$4.43 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EMR Emerson Electric	$2.11	1.46%	N/A	50.48%	68 Years
GS The Goldman Sachs Group	$12.00	1.69%	N/A	27.85%	13 Years
NFLX Netflix	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.03%	N/A	124.64%	16 Years

Latest PFE, GS, EMR, and NFLX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2025	GS The Goldman Sachs Group	quarterly	$4.00	2.3%	8/29/2025	8/29/2025	9/29/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
5/7/2025	EMR Emerson Electric	quarterly	$0.5275	1.96%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EMR Emerson Electric	0.42	0.80	0.59
GS The Goldman Sachs Group	2.26	1.12	0.68
NFLX Netflix	0.58	1.20	1.20
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EMR Emerson Electric	74.30%
GS The Goldman Sachs Group	71.21%
NFLX Netflix	80.93%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
EMR Emerson Electric	0.50%
GS The Goldman Sachs Group	0.55%
NFLX Netflix	1.37%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EMR Emerson Electric	73,000	562.50 million	559.69 million	Optionable
GS The Goldman Sachs Group	46,500	306.84 million	305.15 million	Optionable
NFLX Netflix	14,000	425.57 million	419.74 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, GS, EMR, and NFLX Headlines

Recent News About These Companies

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program

4 hours ago | insidermonkey.com

Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes

July 18 at 12:57 PM | tipranks.com

Pfizer’s BeneFIX Study Update: Key Insights for Investors

July 18 at 12:57 PM | tipranks.com

Pfizer’s INLYTA® Study in Taiwan: Key Insights for Investors

July 18 at 12:57 PM | tipranks.com

Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors

July 18 at 12:08 PM | tipranks.com

Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention?

July 18 at 12:08 PM | tipranks.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by FLC Capital Advisors

July 18 at 11:10 AM | marketbeat.com

63,000 Shares in Pfizer Inc. (NYSE:PFE) Bought by Hussman Strategic Advisors Inc.

July 18 at 10:39 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Alexander Labrunerie & CO. Inc.

July 18 at 9:28 AM | marketbeat.com

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

July 17 at 3:26 PM | benzinga.com

Trade Tracker: Josh Brown Sells Pfizer

July 17 at 2:10 PM | youtube.comY

3 Ultra-Safe Dividend Stocks That Yield Over 5%

July 17 at 11:47 AM | 247wallst.com

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

July 17 at 11:47 AM | cnbc.com

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients

July 17 at 11:18 AM | reuters.com

Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures

July 17 at 11:18 AM | finance.yahoo.com

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount

July 17 at 10:43 AM | tipranks.com

Mystic Asset Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:48 AM | marketbeat.com

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

July 17 at 9:34 AM | investing.com

Pzena Investment Management LLC Increases Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:22 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Trims Stock Position in Pfizer Inc. (NYSE:PFE)

July 17 at 9:14 AM | marketbeat.com

Easterly Investment Partners LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 17 at 9:00 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
3 Upgraded Stocks to Load Up on Before Earnings
By Thomas Hughes | July 8, 2025
View 3 Upgraded Stocks to Load Up on Before Earnings
3 Tech Stocks Poised for Explosive EPS Growth in 2025
By Gabriel Osorio-Mazilli | July 8, 2025
View 3 Tech Stocks Poised for Explosive EPS Growth in 2025

PFE, GS, EMR, and NFLX Company Descriptions

Emerson Electric NYSE:EMR

$144.16 -0.23 (-0.16%)

Closing price 03:59 PM Eastern

Extended Trading

$143.49 -0.67 (-0.46%)

As of 06:13 PM Eastern

Emerson Electric Co., a technology and software company, provides various solutions for customers in industrial, commercial, and consumer markets in the Americas, Asia, the Middle East, Africa, and Europe. It operates in six segments: Final Control, Control Systems & Software, Measurement & Analytical, AspenTech, Discrete Automation, and Safety & Productivity. The Final Control segment provides control, isolation, shutoff, pressure relief, and pressure safety valves, actuators, and regulators for process and hybrid industries. The Measurement & Analytical segment offers intelligent instrumentation measuring the physical properties of liquids or gases, such as pressure, temperature, level, flow, acoustics, corrosion, pH, conductivity, water quality, toxic gases, and flame. The Discrete Automation segment offers solenoid and pneumatic valves, valve position indicators, pneumatic cylinders, air preparation equipment, pressure and temperature switches, electric linear motion solutions, programmable automation control systems, electrical distribution equipment, and materials joining solutions. The Safety & Productivity segment offers tools for professionals and homeowners; pipe-working tools, including pipe wrenches, pipe cutters, pipe threading and roll grooving equipment, battery hydraulic tools; electrical tools; and other professional tools. The Control Systems & Software segment provides distributed control systems, safety instrumented systems, SCADA systems, application software, digital twins, asset performance management, and cybersecurity. The Test & Measurement provides software-connected automated test and measurement systems. The AspenTech segment provides asset optimization software that enables industrial manufacturers to design, operate, and maintain operations for enhancing performance through a combination of decades of modeling, simulation, and optimization capabilities. The company was incorporated in 1890 and is headquartered in Saint Louis, Missouri.

The Goldman Sachs Group NYSE:GS

$708.31 +2.47 (+0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$706.77 -1.54 (-0.22%)

As of 06:50 PM Eastern

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Netflix NASDAQ:NFLX

$1,209.24 -64.93 (-5.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1,209.68 +0.44 (+0.04%)

As of 06:51 PM Eastern

Netflix, Inc. provides entertainment services. It offers TV series, documentaries, feature films, and games across various genres and languages. The company also provides members the ability to receive streaming content through a host of internet-connected devices, including TVs, digital video players, TV set-top boxes, and mobile devices. It has operations in approximately 190 countries. The company was incorporated in 1997 and is headquartered in Los Gatos, California.

Pfizer NYSE:PFE

$24.46 -0.12 (-0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$24.48 +0.02 (+0.10%)

As of 06:51 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time